TRT and Fertility Preservation with hCG and GLP-1 Options

Estimated reading time: 10 minutes

Learn how hCG can preserve spermatogenesis on TRT, where anti-estrogens fit, and when GLP-1 therapy may help men with obesity-related low T. Includes what to monitor.

Key takeaways

TRT suppresses LH, lowering intratesticular testosterone and reducing sperm production.
hCG is the best-supported adjunct to preserve spermatogenesis during TRT by mimicking LH.
SERMs and aromatase inhibitors can raise endogenous T but carry sexual function and bone health concerns with longer-term use.
GLP-1 receptor agonists may raise total testosterone while preserving LH/FSH in men with obesity-related low T; long-term fertility data are limited.
All TRT users should monitor blood pressure and cardiovascular risk per updated FDA class-wide labeling.

Why TRT Threatens Fertility
hCG with Testosterone: The Standard for Preserving Spermatogenesis
Anti-Estrogens: Where SERMs and Aromatase Inhibitors Fit
GLP-1 Receptor Agonists: A Fertility-Sparing Option for Obesity-Related Low T?
Choosing a Path Based on Your Situation
Monitoring and Safety: What to Track and Why
What We Don’t Know Yet
A Note on Cardiovascular Safety and TRT
Conclusion

Why TRT Threatens Fertility

Normal sperm production relies on the hypothalamic–pituitary–gonadal (HPG) axis: the brain releases gonadotropins (LH and FSH), LH signals the testes to make intratesticular testosterone (ITT), and that local testosterone supports spermatogenesis. Exogenous testosterone suppresses this loop. When LH falls, ITT plummets—even if blood testosterone looks healthy—leading to reduced sperm count and, in some cases, azoospermia.

Multiple studies have shown that TRT alone substantially lowers ITT and impairs spermatogenesis. Adding back LH-like signaling with hCG can preserve testicular testosterone at levels compatible with sperm production.

hCG with Testosterone: The Standard for Preserving Spermatogenesis

hCG is a biologic hormone that binds the same receptor as LH on Leydig cells in the testes. By mimicking LH, hCG can maintain ITT during TRT and help preserve sperm production.

What the evidence shows

Studies demonstrate that hCG co-therapy limits the drop in ITT seen with TRT and can sustain or restore semen parameters in many men.
Clinical experience and contemporary reviews describe hCG as having a prominent role in preventing testicular atrophy and preserving fertility for men on TRT, particularly for those planning to conceive in the near to intermediate term.
Individual responses vary. A minority of men may still see significant suppression, underscoring the need for monitoring.

How it’s used in practice

Clinicians often start low-dose hCG alongside TRT, then adjust based on semen analysis, testicular volume, estradiol, and symptoms.
Commonly used regimens in the literature include 250–500 IU subcutaneously 2–3 times per week, personalized to goals and labs. This is shared for context, not as a prescription.

Considerations and side effects

hCG can increase estrogen levels and may contribute to acne, mood changes, or gynecomastia at higher doses. Regular estradiol and hematocrit checks help guide dosing.
Cost and insurance coverage vary.
Injections 2–3 times weekly can be a burden for some patients.

Bottom line: For men on TRT who want to protect fertility, hCG remains the most established and clinically accepted strategy.

Anti-Estrogens: Where SERMs and Aromatase Inhibitors Fit (and Where They Don’t)

Two off-label categories sometimes enter the conversation:

SERMs (e.g., clomiphene citrate) block estrogen feedback at the hypothalamus/pituitary, often increasing LH/FSH and raising endogenous testosterone production without suppressing gonadotropins. Some men use SERM monotherapy in lieu of TRT to avoid HPG-axis shutdown.
Aromatase inhibitors (e.g., anastrozole) reduce conversion of testosterone to estradiol, which may modestly boost LH and testosterone in select contexts.

Where caution is warranted

Evidence directly comparing these agents to hCG for preserving spermatogenesis on TRT is limited and dated.
Long-term SERM or AI use can affect sexual function and bone health. As a result, many specialists avoid positioning anti-estrogens as first-line, long-term fertility-preserving strategies, though they may be used short term or in specific scenarios (for example, as a bridge when tapering off TRT for conception, or to address symptomatic hyperestrogenism).
If used, careful monitoring of bone markers, estradiol, and clinical symptoms is essential.

GLP-1 Receptor Agonists: A Fertility-Sparing Option for Obesity-Related Low T?

A major shift in the last two years is the emergence of GLP-1 receptor agonists—medications like semaglutide, liraglutide, dulaglutide, and exenatide—showing benefits for testosterone and potential fertility preservation in men with obesity-related or functional hypogonadism.

What’s new

A 2026 systematic review of 10 studies (639 men) found GLP-1RAs were associated with increases in total testosterone, particularly in men with obesity, type 2 diabetes, or functional hypogonadism, while preserving LH and FSH. Unlike TRT, these agents did not suppress the HPG axis.
Some studies reported improvements in semen parameters in obese or hypogonadal men; healthy-weight men generally saw no semen changes.
Free testosterone results were inconsistent, partly due to increases in sex hormone binding globulin (SHBG) with weight loss.
The same agents reliably improved metabolic health (weight reduction, glycemic control).

Why it matters

For men whose low testosterone is closely tied to obesity and insulin resistance, GLP-1RA therapy may address the root metabolic drivers, potentially improving symptoms and total testosterone without shutting down gonadotropins—and therefore posing less risk to sperm production.

These medications are not FDA-approved for hypogonadism or fertility; their use in this context is off-label. Also, long-term fertility outcomes beyond ~24 weeks are not yet known.

What’s next

The SEMAT clinical trial, launched in 2024, is comparing semaglutide head-to-head with injectable testosterone undecanoate in men with type 2 diabetes, obesity, and functional hypogonadism. Primary outcomes include sperm quality and symptom change over 24 weeks. Results will help clarify whether GLP-1RA therapy can match or exceed TRT for symptoms while better preserving fertility.

Takeaway: For men with obesity-driven low testosterone who prioritize fertility, GLP-1RAs may be a meaningful option to discuss—either before initiating TRT or as an adjunct in a comprehensive plan. Evidence is growing but still limited; individualized decisions and monitoring are key.

Choosing a Path Based on Your Situation

Already on TRT and want to maintain or restore fertility:
- Discuss adding hCG to mimic LH and support spermatogenesis. Establish a baseline semen analysis, then repeat at intervals (for example, every 3–6 months).
- Expect dose adjustments based on semen results, estradiol, and clinical response.
- If semen parameters remain poor, your clinician may consider modifying TRT dose, adjusting hCG, or short-term use of other agents.
Planning to start TRT and fertility is a priority:
- Consider starting TRT with hCG from day one to minimize testicular atrophy and preserve spermatogenesis.
- If you have obesity or type 2 diabetes and symptoms of low testosterone, ask about GLP-1RA therapy as a first step that may improve testosterone levels without suppressing LH/FSH.
Functional hypogonadism with obesity/insulin resistance:
- GLP-1RA monotherapy may improve total testosterone and semen parameters in some men while supporting weight loss and metabolic health.
- Lifestyle interventions (sleep, resistance training, nutrition) remain foundational.
Microdosing strategies:
- Some clinics use lower-dose TRT alongside hCG to target symptom control while protecting fertility. Protocols are individualized, emphasizing lab- and semen-guided adjustments rather than fixed recipes.
Coming off TRT to conceive:
- Transition plans sometimes include hCG and/or a SERM temporarily to re-stimulate the axis. Timelines and choices vary; specialist oversight is recommended.

Monitoring and Safety: What to Track and Why

Protecting fertility on TRT isn’t just about picking the right agents—it’s about tracking the right endpoints and side effects.

Baseline assessments

Semen analysis and testicular volume
Total and free testosterone, SHBG, LH, FSH, estradiol
Hematocrit/hemoglobin
Blood pressure and cardiovascular risk profile
Metabolic markers (A1c, fasting glucose, lipids) if weight or glycemic concerns are present

Ongoing monitoring

Semen analysis every 3–6 months while adjusting therapy
Estradiol and hematocrit when using hCG with TRT
Blood pressure at regular intervals for all TRT users; FDA class-wide labeling highlights BP increases across testosterone formulations.
For GLP-1RAs: monitor weight, glycemic control, and gastrointestinal tolerability; discuss gallbladder risks if relevant

When to seek reassessment

Azoospermia or sharp declines in sperm count
Marked testicular atrophy or pain
Signs of elevated estradiol (worsening gynecomastia, irritability) or high hematocrit
Persistent hypertension on TRT

What We Don’t Know Yet

Long-term fertility outcomes (including pregnancy rates) in men using hCG with continuous TRT
The optimal hCG dose and titration strategy for maintaining spermatogenesis during TRT
How GLP-1RAs compare directly with TRT (with or without hCG) for symptom relief and sperm quality over longer periods
The precise role, if any, for long-term anti-estrogens in fertility-preserving care, given bone and sexual function concerns
Whether combining hCG with a GLP-1RA offers additive benefits for both fertility and metabolic health

A Note on Cardiovascular Safety and TRT

The FDA updated testosterone product labeling in 2025 after a large outcomes trial showed non-inferiority versus placebo for major adverse cardiovascular events (7.0% versus 7.3%). At the same time, regulators added class-wide language highlighting blood pressure increases across testosterone formulations and the need for monitoring. For men on TRT—especially those combining therapies—it’s prudent to keep cardiovascular risk management front and center.

Conclusion

If you’re weighing TRT and future fatherhood, there are real, evidence-informed strategies to lower fertility risk:

hCG remains the mainstay for preserving spermatogenesis during TRT.
Anti-estrogens can play a role in select, short-term contexts but are not well supported for long-term fertility preservation.
GLP-1RAs are an emerging fertility-sparing option in men with obesity-driven hypogonadism, with promising hormonal and metabolic effects but still-limited fertility data.

The right approach depends on your diagnosis, priorities, and response to therapy. A plan built around clear goals, baseline and follow-up semen testing, hormone and safety labs, and regular blood pressure monitoring gives you the best chance of symptom relief without sacrificing family plans. If you’re considering changes to your regimen, bring your questions—and your latest labs—to a clinician experienced in hormone and fertility care.

Disclaimer

This article is for informational purposes only and does not constitute medical advice, diagnosis, or treatment. Always speak with a qualified clinician about your personal health, medications, and fertility goals.

TRT and Fertility Preservation with hCG and GLP-1 Options